Calcium Homeostasis

Why calcium homeostasis matters

• Ionized calcium gates every action potential. Extracellular calcium adsorbs onto voltage-gated sodium channels and raises their firing threshold. A drop of just 0.2 mM in ionized calcium is enough to make nerves fire spontaneously and trigger tetany; a rise blunts excitability into stupor and arrhythmia. The setpoint is defended minute to minute, which is why the body will demineralize its own skeleton before it lets blood calcium drift.
• Contraction, secretion, and clotting all depend on it. Calcium is the trigger for cardiac and skeletal muscle contraction, neurotransmitter release at the synapse, hormone exocytosis, and it is factor IV of the coagulation cascade — which is why blood-bank blood is anticoagulated simply by chelating calcium with citrate.
• The skeleton is a mineral bank, not just scaffolding. About 1 kg of calcium is stored as hydroxyapatite, and the system continuously withdraws and redeposits it. Chronic PTH excess (primary hyperparathyroidism, prevalence ~1 in 1000, rising with age) drains that bank and causes the classic "stones, bones, groans, and psychiatric moans."
• Vitamin D deficiency is a global disease. Rickets in children and osteomalacia in adults follow inadequate calcitriol; the discovery that UV light and cod-liver oil cured rickets in the 1920s (Mellanby, McCollum, Huldschinsky) ranks among the great nutritional victories. Deficiency remains common at high latitudes and in darker-skinned or veiled populations.
• It is a dominant reason for kidney and endocrine medicine. Chronic kidney disease wrecks calcium homeostasis (failed 1-alpha-hydroxylation, phosphate retention, secondary hyperparathyroidism, renal osteodystrophy). Calcimimetics like cinacalcet and vitamin D analogs are frontline drugs; measuring PTH, 25-OH-D, calcium, and phosphate together is routine.
• Pregnancy and lactation stress-test the system. A lactating mother transfers ~200–300 mg of calcium per day into breast milk, driven partly by PTH-related peptide (PTHrP) from the breast; she reversibly loses 3–5% of skeletal mineral, then rebuilds it after weaning — a controlled demonstration of the bone reservoir in action.

Common misconceptions

• "Low calcium causes weakness because calcium powers contraction." Backwards. The intracellular calcium that powers contraction is unaffected by mild hypocalcemia. It is the extracellular ionized calcium guarding nerve excitability that falls, so nerves fire spontaneously and muscles go into spasm — tetany, not weakness.
• "Calcitonin is the main brake on calcium." In humans it is nearly vestigial. Thyroidectomized patients with no calcitonin have normal calcium, and medullary thyroid cancers pumping out huge calcitonin do not become hypocalcemic. The real day-to-day regulation is dialing PTH up and down; calcitonin is clinically most useful as a tumor marker.
• "PTH is bad for bone." Continuous high PTH is catabolic and destroys bone. But intermittent PTH is anabolic — teriparatide (recombinant PTH 1–34), given as a once-daily injection, is a leading osteoporosis drug that builds bone. The dose schedule flips the effect.
• "Vitamin D is a vitamin." Functionally it is a steroid hormone. The active form, calcitriol, binds a nuclear receptor (VDR) and changes gene transcription, exactly like cortisol or thyroid hormone. It is called a vitamin only because we can be dependent on the diet when skin synthesis is insufficient.
• "Total serum calcium is what matters." Only the ~45% that is ionized is regulated and active; another ~45% is bound to albumin. Hypoalbuminemia lowers total calcium with no symptoms. The correction is roughly +0.2 mM per 10 g/L that albumin sits below normal — or just measure ionized calcium directly.
• "PTH raises phosphate along with calcium." The opposite. PTH is phosphaturic — it internalizes the proximal-tubule NaPi-IIa cotransporter and dumps phosphate in the urine. This keeps the calcium-phosphate product from precipitating and lets calcium rise cleanly. FGF23 from bone reinforces the phosphate excretion.

How calcium homeostasis works

The whole system is a negative-feedback loop built around a single sensor. The calcium-sensing receptor (CaSR), a class C G-protein-coupled receptor on parathyroid chief cells, uses extracellular ionized calcium itself as its ligand. When calcium is on target or high, CaSR signaling suppresses PTH secretion; when ionized calcium falls even slightly, that suppression lifts and PTH is released within seconds. PTH secretion is exquisitely steep around the setpoint — a small change in calcium produces a large swing in PTH.

PTH raises calcium on three fronts. In bone, PTH binds the PTH1 receptor on osteoblasts and osteocytes (osteoclasts have none). Those cells respond by upregulating RANKL and suppressing its decoy osteoprotegerin; RANKL then engages RANK on osteoclast precursors, driving them to mature and resorb mineralized matrix, liberating calcium and phosphate. In the kidney, PTH increases calcium reabsorption in the distal convoluted tubule through the apical channel TRPV5, calbindin-D28k, and the basolateral exchanger NCX1, while simultaneously blocking phosphate reabsorption in the proximal tubule by internalizing NaPi-IIa. And in the kidney PTH induces 1-alpha-hydroxylase (CYP27B1), the enzyme that makes active vitamin D. The bone and kidney arms act in minutes to hours; the vitamin D arm plays out over a day or two.

Vitamin D opens the gut. Cholecalciferol (D3) is made in skin from 7-dehydrocholesterol under UVB, then hydroxylated in the liver to 25-hydroxyvitamin D — the circulating storage form clinicians measure. The PTH-driven renal 1-alpha-hydroxylase converts it to 1,25-dihydroxyvitamin D3, calcitriol. Calcitriol enters duodenal enterocytes, binds the nuclear vitamin D receptor (VDR), which heterodimerizes with RXR and transcriptionally induces the apical calcium channel TRPV6, the cytosolic shuttle calbindin-D9k, and the basolateral pump PMCA1b — the machinery of active transcellular calcium absorption. With adequate calcitriol the gut absorbs 30–40% of dietary calcium; without it, only 10–15%.

Calcitonin closes the loop the other way. When calcium rises, the parafollicular C cells of the thyroid release calcitonin, a 32-residue peptide that binds calcitonin receptors on osteoclasts and makes them retract their ruffled border and stop resorbing within minutes, and modestly raises renal calcium excretion. In humans this arm is weak; in fish it is dominant. Net result: a two-hormone push (PTH, calcitriol) and a one-hormone pull (calcitonin) that hold ionized calcium within a few percent of setpoint, buffered against the enormous skeletal reservoir.

The three hormones compared

Feature	Parathyroid hormone (PTH)	Calcitriol (active vit D)	Calcitonin
Source	Parathyroid chief cells	Kidney (from liver 25-OH-D)	Thyroid parafollicular C cells
Chemistry	84-aa peptide	Secosteroid hormone	32-aa peptide
Effect on blood Ca	Raises	Raises	Lowers
Bone	↑ resorption (via RANKL)	Supports resorption / mineralization	↓ osteoclast activity
Kidney	↑ Ca reabsorption, ↓ phosphate	↑ Ca & phosphate reabsorption	↑ Ca excretion (mild)
Gut	Indirect (makes calcitriol)	↑ Ca absorption (TRPV6/calbindin)	None
Receptor	PTH1R (GPCR)	Nuclear VDR	Calcitonin receptor (GPCR)
Speed	Seconds–hours	~1–2 days	Minutes
Human importance	Dominant regulator	Essential for absorption	Minor / vestigial

When it breaks: hypocalcemia vs hypercalcemia

Property	Hypocalcemia (low Ca)	Hypercalcemia (high Ca)
Ionized Ca	Below ~1.1 mM	Above ~1.3 mM
Nerve/muscle	Hyperexcitable → tetany, spasm	Depressed → weakness, lethargy
Classic signs	Chvostek, Trousseau, perioral tingling, laryngospasm	Stones, bones, groans, psychiatric moans
Common causes	Hypoparathyroidism (post-thyroidectomy), vitamin D deficiency, CKD, hypomagnesemia	Primary hyperparathyroidism, malignancy (PTHrP), vitamin D toxicity
PTH pattern	Low in hypoPTH; high in vit-D deficiency (secondary)	High in primary hyperPTH; low in malignancy
Bone consequence	Rickets / osteomalacia if vit-D driven	Osteitis fibrosa cystica, fractures
ECG	Prolonged QT	Shortened QT
Emergency Rx	IV calcium gluconate	IV saline, then bisphosphonate/calcitonin

Famous experiments and history

• Collip isolates PTH (1925). James Bertram Collip — the same biochemist who purified insulin with Banting and Best — prepared an active hot-HCl extract of parathyroid glands that reversed the lethal tetany of parathyroidectomized dogs and raised their blood calcium. This proved a single glandular hormone controlled calcium and launched the field.
• MacCallum and Voegtlin (1908). Working at Johns Hopkins, they showed that the tetany following parathyroid removal was due specifically to low blood calcium and could be relieved by calcium infusion — establishing calcium, not the nerves themselves, as the culprit and the parathyroids as its guardians.
• Copp discovers calcitonin (1962). Douglas Harold Copp, perfusing the thyroid–parathyroid region of dogs with high-calcium blood, found the calcium fell faster than removing the glands could explain. He inferred a fast-acting calcium-lowering hormone he named "calcitonin," later localized to the thyroid C cells.
• The vitamin D / rickets breakthrough (1919–1922). Kurt Huldschinsky cured rachitic children with UV lamps in 1919; Edward Mellanby produced and cured rickets in dogs by diet; Elmer McCollum's group identified the fat-soluble anti-rachitic factor as a distinct "vitamin D" in 1922, separating it from vitamin A in cod-liver oil.
• Cloning the calcium-sensing receptor (1993). Edward M. Brown and colleagues cloned CaSR from bovine parathyroid, proving that the parathyroid cell literally "tastes" extracellular calcium through a GPCR. This explained familial hypocalciuric hypercalcemia (inactivating mutations) and autosomal dominant hypocalcemia (activating mutations), and gave the target for the calcimimetic drug cinacalcet.
• The RANKL/OPG axis (1997–1998). Amgen and other groups identified osteoprotegerin and its ligand RANKL as the master switch of osteoclast formation — the molecular relay by which PTH signals bone to release calcium. It became the target of denosumab, an anti-RANKL antibody now used for osteoporosis and bone metastases.